AIDS Malignancy Consortium
Trial Pipeline
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
NCT05077527
Trial of Ixazomib for Kaposi Sarcoma
NCT04305691
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
NCT04949464
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
NCT04139304
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
NCT02797470
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
NCT02437851
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
NCT02135419
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
NCT01946217
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
NCT00006264
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for AIDS Malignancy Consortium Shows
According to the ClinicalTrials.gov registry, AIDS Malignancy Consortium is linked to 11 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 45% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 36% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for AIDS Malignancy Consortium reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 7 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for AIDS Malignancy Consortium is HIV Infection with 7 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.